Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.36 |
| ▸ | CNR1 | P21554 | 6/20 | 0.34 |
| ▸ | CNR2 | P34972 | 5/20 | 0.34 |
| ▸ | PPARG | P37231 | 3/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.32 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13585976 | 0.74 | AGTR1 (0.39) | AGTR1AGTR2 | |
| SCHEMBL27682489 | 0.73 | TLR8 (0.36) | TLR8CNR1CNR2AGTR1AGTR2 | |
| SCHEMBL3426317 | 0.72 | ALOX12 (0.46) | SMN1; SMN2 | |
| SCHEMBL3219891 | 0.72 | CNR1 (0.48) | CNR1CNR2 | |
| SCHEMBL3225639 | 0.69 | TLR8 (0.46) | TLR8CNR1 | |
| SCHEMBL251852 | 0.68 | MEN1 (0.31) | — | |
| SCHEMBL251851 | 0.67 | ALDH1A1 (0.30) | LMNA | |
| SCHEMBL11510479 | 0.67 | SMN1; SMN2 (0.44) | SMN1; SMN2LMNATSHRAGTR1AGTR2 | |
| SCHEMBL11557183 | 0.66 | KDR (0.39) | TLR8SMN1; SMN2LMNATSHR | |
| SCHEMBL6822701 | 0.65 | MAPK1 (0.32) | SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-1995000499-A1 | HERBICIDAL SUBSTITUTED 1,5-DIARYL-1H-1,2,4-TRIAZOL-3-CARBOXAMIDES | BAYER AKTIENGESELLSCHAFT (DE) | 1995-01-05 | — | — | WO | claimed |
| US-7781471-B2 | Diaryl triazolmethylamine derivatives, preparation and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2010-08-24 | — | — | US | disclosed |
| EP-1966167-B1 | DIARYLTRIAZOLMETHYLAMINE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI AVENTIS (FR) | 2010-06-16 | — | — | EP | disclosed |
| EP-1542678-B1 | 1H-1,2,4-TRIAZOLE-3-CARBOXAMIDE DERIVATIVES AS CANNABINOID-CB sb 1 /sb RECEPTOR LIGANDS | SOLVAY PHARM BV (NL) | 2010-02-24 | — | — | EP | disclosed |
| US-20080293794-A1 | DIARYLTRIAZOLMETHYLAMINE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2008-11-27 | — | — | US | disclosed |
| EP-1966167-A1 | DIARYLTRIAZOLMETHYLAMINE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | sanofi-aventis (FR) | 2008-09-10 | — | — | EP | disclosed |
| US-7319110-B2 | 1H-1,2,4-triazole-3-carboxamide derivatives having cannabinoid-CB1 receptor agonistic, partial agonistic, inverse agonistic or antagonistic activity | SOLVAY PHARMACEUTICALS B.V. (NL) | 2008-01-15 | — | — | US | disclosed |
| WO-2007068814-A1 | DIARYLTRIAZOLMETHYLAMINE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2007-06-21 | — | — | WO | disclosed |
| EP-1753413-A2 | NOVEL MEDICAL USES OF COMPOUNDS SHOWING CB SB 1/SB -ANTAGONISTIC ACTIVITY AND COMBINATION TREATMENT INVOLVING SAID COMPOUNDS | Solvay Pharmaceuticals GmbH (DE) | 2007-02-21 | — | — | EP | disclosed |
| US-20050124660-A1 | Compounds for treatment of diseases using enzyme inhibitors, cognition activators for nervous system disorders, psychological disorders or obesity in children | SOLVAY PHARMACEUTICALS GMBH (DE) | 2005-06-09 | — | — | US | disclosed |
| WO-2005039550-A2 | NOVEL MEDICAL USES OF COMPOUNDS SHOWING CB1-ANTAGONISTIC ACTIVITY AND COMBINATION TREATMENT INVOLVING SAID COMPOUNDS | SOLVAY PHARMACEUTICALS GMBH (DE) | 2005-05-06 | — | — | WO | disclosed |
| US-20040106614-A1 | 1H-1,2,4-triazole-3-carboxamide derivatives having cannabinoid-CB1 receptor agonistic, partial agonistic, inverse agonistic or antagonistic activity | SOLVAY PHARMACEUTICALS B.V. (NL) | 2004-06-03 | — | — | US | disclosed |
| WO-1995000499-A1 | HERBICIDAL SUBSTITUTED 1,5-DIARYL-1H-1,2,4-TRIAZOL-3-CARBOXAMIDES | BAYER AKTIENGESELLSCHAFT (DE) | 1995-01-05 | — | — | WO | disclosed |
| WO-1995000499-A1 | HERBICIDAL SUBSTITUTED 1,5-DIARYL-1H-1,2,4-TRIAZOL-3-CARBOXAMIDES | BAYER AKTIENGESELLSCHAFT (DE) | 1995-01-05 | — | — | WO | disclosed |
| WO-1995000499-A1 | HERBICIDAL SUBSTITUTED 1,5-DIARYL-1H-1,2,4-TRIAZOL-3-CARBOXAMIDES | BAYER AKTIENGESELLSCHAFT (DE) | 1995-01-05 | — | — | WO | disclosed |
| EP-0189300-B1 | DIHYDROTRIAZOLE DERIVATIVES AND THEIR USE AS HERBICIDES | KUREHA KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 1991-03-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293794-A1 | DIARYLTRIAZOLMETHYLAMINE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | LTB4R2, LTB4R, CYSLTR1 | TLR8 1089/4885CNR1 31/4885CNR2 15/4885 |
| US-20040106614-A1 | 1H-1,2,4-triazole-3-carboxamide derivatives having cannabinoid-CB1 receptor agonistic, partial agonistic, inverse agonistic or antagonistic activity | CNR1, CNR2, GPR3 | TLR8 1647/4885CNR1 1/4885CNR2 2/4885 |
| US-20050124660-A1 | Compounds for treatment of diseases using enzyme inhibitors, cognition activators for nervous system disorders, psychological disorders or obesity in children | PNLIP, DLAT, LPCAT3 | TLR8 1262/4885CNR1 46/4885CNR2 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.